Nuveen LLC Acquires New Holdings in Altimmune, Inc. $ALT

Key Points

• Nuveen LLC has acquired 263,898 shares of Altimmune, Inc., valued at approximately $1.3 million, representing about 0.34% ownership of the company.
• Altimmune's stock has seen varied analyst ratings, with five analysts giving it a Buy rating, while one rated it as Sell, and a consensus price target of $17.40.
• The company reported an earnings per share (EPS) of ($0.27) for the last quarter, exceeding expectations while still reflecting significant operational challenges.

Nuveen LLC purchased a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 263,898 shares of the company's stock, valued at approximately $1,304,000. Nuveen LLC owned about 0.34% of Altimmune as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of ALT. GAMMA Investing LLC grew its stake in Altimmune by 214.2% in the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock valued at $34,000 after buying an additional 4,598 shares during the last quarter. Magnus Financial Group LLC acquired a new position in Altimmune in the 1st quarter valued at about $50,000. Headland Capital LLC acquired a new position in Altimmune in the 1st quarter valued at about $50,000. Sunbelt Securities Inc. grew its stake in Altimmune by 356.8% in the 4th quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company's stock valued at $79,000 after buying an additional 8,470 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Altimmune in the 4th quarter valued at about $88,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Price Performance

Shares of Altimmune stock traded down $0.10 on Thursday, reaching $3.59. 890,953 shares of the stock were exchanged, compared to its average volume of 3,705,018. The firm's 50 day moving average is $3.91 and its 200-day moving average is $5.01. Altimmune, Inc. has a one year low of $2.90 and a one year high of $11.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. The firm has a market cap of $316.40 million, a PE ratio of -3.02 and a beta of 0.18.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ALT shares. The Goldman Sachs Group raised shares of Altimmune to a "strong sell" rating in a report on Thursday, July 10th. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Wednesday, August 13th. UBS Group cut their price objective on shares of Altimmune from $26.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, JMP Securities cut their price objective on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a report on Thursday, July 10th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $17.40.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.